1. Targos and AKESOgen form strategic partnership to enable a comprehensive biomarker
service for clinical trials and molecular pathology
Kassel, Germany and Norcross, GA, USA. May 21, 2014. Targos Molecular Pathology GmbH, a leader in clinical
biomarker services and AKESOgen Inc., a leading US genomics and personalized medicine services company today
announced a global commercial partnership to offer the pharmaceutical and biotech industry a wide ranging package of
traditional pathology and new cutting edge molecular biomarker solutions that provides clients a wide ranging menu of
biomarker offerings including IHC, FISH, molecular and cytogenomic options.
"We were attracted to AKESOgen because of their outstanding quality and service orientated approach as well as their
know how in molecular genetic technologies. The unique partnership with AKESOgen will allow us to expand our
comprehensive suite of services that have successfully supported the pharma market for nine years. Through this
collaboration, we will be able to better serve all of our customers in the US, with the unmatched quality and value-added
services that we have established over the past nine years. " said Dr. Thomas Henkel, CEO of Targos.
"Targos is an outstanding leader in Europe in molecular pathology services and teaching. We are delighted with this
partnership and to support the high quality services in pathology provided by Targos as well as enable a footprint to
operate out of the US.” commented Robert Boisjoli, CEO of AKESOgen.
The partnership will harness the combined strengths of both companies. AKESOgen will provide its 14,000 sq. ft site
and facilities near Atlanta, GA, USA as well as world class genetic and molecular expertise which will complement the
undoubted quality and strengths of Targos’s companion diagnostics, pathology and biomarker capabilities.
-ENDS-
Contact details
George L. Kumar, PhD, MBA, Vice President of Marketing and Scientific Affairs, Targos, GmbH.
E-mail: George.Kumar@targos-inc.com
Mark Bouzyk, PhD, Chief Scientific Officer, AKESOgen, Inc.
E-mail: mbouzyk@akesogen.com
About Targos: Targos core service business is to provide highly standardized development and application of clinical
biomarkers for the international pharmaceutical and diagnostic industry. The company has supported more than 100
international clinical trials since 1999, which have led to the successful approval of several targeted therapies and IVDs
for our customers. The expert team of on-site clinical pathologists operates in a professional environment of project
management, logistics, data and quality management. Targos also supports the introduction of new Companion
Diagnostic assays into the market. Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food

2. and Drug Administration (FDA). Targos Molecular Pathology GmbH is accredited by the College of American
Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).
About AKESOgen: AKESOgen is a CLIA compliant integrated genomics and pharmacogenetics company providing
biorepository services and high-throughput, biomarker profiling and genomics analysis utilizing different types of
markers (e.g. DNA, mRNA, miRNA, methylation) for the clinical and R&D market. A private company based in
Atlanta, GA, AKESOgen is a genomics contract research organization that services the academic, pharmaceutical,
biotechnology, clinical testing and government sectors. The company supports a number of world class organizations
including the CDC, the US Department of Veteran’s Affairs, the American Cancer Society and Kaiser Permanente.
AKESOgen’s flagship clinical test is a clinical cytogenomics array for a wide-ranging spectrum of cancers. AKESOgen
also provides expertise in biobanking, assay development and all ancillary services in a purpose-built facility. For more
information, visitwww.akesogen.com